Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07563881 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
A Phase 3 study, sponsored by Rapport Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 333
- Enrollment target
NCT07563881 is a Phase 3 study that is actively recruiting participants, run by Rapport Therapeutics. The registered enrollment target is 333 participants.
The verdict
NCT07563881, a Phase 3 study, is actively recruiting participants, sponsored by Rapport Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 333 participants
- Enrollment target
Study Summary
This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.
Interventions
- OTHER Placebo
- DRUG RAP-219
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 333 participants |
| Start Date | 2026-06-05 |
| Est. Completion | 2029-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07563881
The ClinicalTrials.gov registry entry for NCT07563881 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 333 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rapport Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07563881 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07563881 about?
NCT07563881 is a clinical study titled "Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1". This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.
What is the current status of trial NCT07563881?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 333 participants. The study started on 2026-06-05. Estimated completion is 2029-09.
What interventions are being tested in trial NCT07563881?
The interventions under investigation include: Placebo (OTHER), RAP-219 (DRUG).
Who is sponsoring clinical trial NCT07563881?
This trial is sponsored by Rapport Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.